anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epithelial-mesenchymal transition (EMT) is a crucial mechanism that facilitates cancer cell metastasis. Despite its importance, the clinical significance of EMT in gastric cancer (GC) patients has yet to be clearly demonstrated. For gauging the extent of EMT in GC, we employed gene set variation analysis to score 807 patient samples from two large cohorts: TCGA and GSE84437. In both cohorts, EMT high GC showed a significant association with worse overall survival (hazard ratio (HR) = 1.74, p = 0.011 and HR = 2.01, p < 0.001, respectively). This association was stronger when considering the EMT signature score compared to the individual expressions of EMT-related genes (CDH1, CDH2, VIM, and FN1). While the EMT signature level did not differ among various cancers, high EMT signature specifically correlated with survival in GC alone. Mucinous and diffuse histological types exhibited higher EMT levels compared to others (p < 0.001), and the EMT signature level was correlated with tumor depth and AJCC stage (all p < 0.001). Interestingly, the EMT score was an independent factor for overall and disease-specific survival (multivariate; p = 0.006 and 0.032, respectively). EMT high GC displayed a lower fraction of Th1 cells and a higher fraction of dendritic cells, M1 macrophages and several stromal cells. EMT high GC exhibited an inverse correlation with cell proliferation-related gene sets. While they significantly enriched multiple pro-cancerous gene sets, such as TGF-β signaling, hypoxia, and angiogenesis. The presence of EMT signature in a bulk tumor was linked to TGF-β signaling, hypoxia, and angiogenesis, and was also associated with poorer survival outcomes in GC patients.
COVID-19 has a range of complications, from no symptoms to severe pneumonia. It can also affect multiple organs including the nervous system. COVID-19 affects the brain, leading to neurological symptoms such as delirium. Delirium, a sudden change in consciousness, can increase the risk of death and prolong the hospital stay. However, research on delirium prediction in patients with COVID-19 is insufficient. This study aimed to identify new risk factors that could predict the onset of delirium in patients with COVID-19 using machine learning (ML) applied to nursing records. This retrospective cohort study used natural language processing and ML to develop a model for classifying the nursing records of patients with delirium. We extracted the features of each word from the model and grouped similar words. To evaluate the usefulness of word groups in predicting the occurrence of delirium in patients with COVID-19, we analyzed the temporal changes in the frequency of occurrence of these word groups before and after the onset of delirium. Moreover, the sensitivity, specificity, and odds ratios were calculated. We identified (1) elimination-related behaviors and conditions and (2) abnormal patient behavior and conditions as risk factors for delirium. Group 1 had the highest sensitivity (0.603), whereas group 2 had the highest specificity and odds ratio (0.938 and 6.903, respectively). These results suggest that these parameters may be useful in predicting delirium in these patients. The risk factors for COVID-19-associated delirium identified in this study were more specific but less sensitive than the ICDSC (Intensive Care Delirium Screening Checklist) and CAM-ICU (Confusion Assessment Method for the Intensive Care Unit). However, they are superior to the ICDSC and CAM-ICU because they can predict delirium without medical staff and at no cost.
INTRODUCTION: CXCR4/CXCL12 axis regulates cell proliferation, survival, and differentiation, as well as the homing and mobilization of hematopoietic stem cells (HSCs) from bone marrow niches to the peripheral blood. Furthermore, CXCR4 and CXCL12 are key mediators of cross-talk between hematological malignancies and their microenvironments. CXCR4 overexpression drives disease progression, boosts tumor cell survival, and promotes chemoresistance, leading to poor prognosis.
AREAS COVERED: In light of these discoveries, scientific investigations, and clinical trials have underscored the therapeutic promise found in small-molecule antagonists like plerixafor, peptides/peptidomimetics, such as BKT140, monoclonal antibodies like PF-06747143 and ulocuplumab, as well as microRNAs. Their efficacy is evident in reducing tumor burden, inducing apoptosis and sensitizing malignant cells to conventional chemotherapies. This overview delves into the pathogenic role of the CXC4/CXCL12 axis in hematological neoplasms and examines the clinical application of key CXCR4 antagonists.
EXPERT OPINION: The information collectively emphasizes the potential of CXCR4 antagonists as a therapeutic strategy for hematologic malignancies, showcasing advancements in preclinical and clinical studies. As these therapeutic strategies progress through clinical trials, their potential to reshape the prognosis of hematologic malignancies will become increasingly apparent.
Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training. The physicians assessed the participants and appropriately adjusted the settings of the mechanical ventilation modules to gradually reduce the participants' dependence on mechanical ventilation. Hand bicycle training was conducted by nurse practitioners once a day. The participants' bedhead was raised, and the participants held the cycle ergometer with both hands once they could tolerate upright positions for 15-20 minutes. Training intensity was targeted at the level of symptom limitation, on the basis of a modified Borg scale rating of 3-5. Intermittent and short-term periods of rest were allowed for participants to achieve the goal of a total of 15-20 minutes exercise session.
Health outcomes of chronically ill low-income adults are costly in both fiscal and human terms. Although advances have been made in understanding how nurse case management (NCM) can contribute to self-management (SM) behaviors, the factors that contribute to sustained SM behaviors in low-income African American populations are not well understood. This study will examine the impact of Ecological Nurse Case Management (ENCM) on self-management behaviors, health status, and self-efficacy of poor, chronically ill, African American adults. In addition, we will explore moderating effects to determine if the ENCM intervention is differentially effective based on gender or perceived stress. The study will use the UWM Automated Community Health Information System, a relational electronic health record, to document the individualized ECNM intervention and dose of the intervention. The specific study aims are to: 1) examine differences between an ENCM treated group and a comparison group on self-efficacy, SM behaviors, and health status to establish effect sizes needed for a future large randomized controlled trial; 2) explore the dose-response of specific elements of the ENCM intervention; and 3) examine moderating effects of gender and perceived stress on the intervention effect. This is a two-group randomized experimental study with repeated measurements. Clients in the treatment group (n=25) will receive the individualized ENCM and those in the comparison group (n=25) will receive usual clinic care. Data will be collected at baseline, 1, 3, and 6 months to capture the immediate, short and longer term effects of the intervention. Acknowledging the small sample size, mixed models for repeated measures data (at baseline and M1, 3, and 6 post-intervention) will be fit to interactions involving moderating variables of gender and stress. The ENCM intervention draws on evidence that given the proper tools (i.e., knowledge, skills and support), individuals can learn to better self-manage their symptoms on a day to day basis and better utilize the health care resources available to them.
Patients admitted to primary stroke centres do not have access to the same level of stroke expertise on site as do patients admitted to comprehensive stroke centres, resulting in increased length of stay with implications for access to stroke rehabilitation. Virtual access to stroke experts has been used in hyperacute stroke care through programs such as Ontario Telestroke, but this has not been routinely used for acute inpatient management. The investigators propose a system to provide virtual access to the stroke neurology team to patients admitted with stroke in a primary stroke centre. Patients at the General Campus of the Ottawa Hospital are currently admitted to Internal Medicine; this includes scheduled virtual assessment with a stroke neurologist and advanced practice nurse/interdisciplinary support to review investigations, results, and evaluations to identify stroke etiology, propose appropriate therapy, and guide decision-making and multidisciplinary assessment, similar to services provided to patients admitted to the Civic Campus. This will be developed with the assistance of Internal Medicine and will utilize technologies and assessment tools and strategies already being used for provision of virtual care in other settings. The goal of this project will be to prove that patients in primary stroke centres, with the assistance of virtual care, can benefit from the expertise available at comprehensive centers throughout their stay, and that this will result in an improved quality of care with benefits for patients, hospitals, and the community.
This preparation is specifically designed for use with “three-way catheters or with other catheter systems permitting continuous irrigation of the urinary bladder. The usual irrigation dose is one 1-mL ampul a day for up to 10 days. 

Using strict aseptic techniques, the contents of 1-mL ampul of Neomycin and Polymyxin B Sulfates Solution for Irrigation should be added to a 1,000-mL container of isotonic saline solution. This container should then be connected to the inflow lumen of the “three-way” catheter which has been inserted with full aseptic precautions; use of a sterile lubricant is recommended during insertion of the catheter. The outflow lumen should be connected, via a sterile disposable plastic tube, to a disposable plastic collection bag. Stringent procedures, such as taping the inflow and outflow junction at the catheter, should be observed when necessary to insure the junctional integrity of the system.

For most patients, the inflow rate of the 1,000-mL saline solution of neomycin and polymyxin B should be adjusted to a slow drip to deliver about 1,000 mL every 24 hours. If the patient’s urine output exceeds 2 liters per day, it is recommended that the inflow rate be adjusted to deliver 2,000 mL of the solution in a 24-hour period.

It is important that the rinse of the bladder be continuous; the inflow or rinse solution should not be interrupted for more than a few minutes. 

Preparation of the irrigation solution should be performed with strict aseptic techniques. The prepared solution should be stored at 4°C, and should be used within 48 hours following preparation to reduce the risk of contamination with resistant microorganisms.
BACKGROUND: Intimal hyperplasia is a normal adaptive feature of arteries in response to injuries, which include invasive vascular interventions. Its development limits the long-term success of bypass grafts. Various pharmacological agents have been successfully employed in experimental models to reduce the degree of intimal hyperplasia. In our study, we investigated the efficacy of dexamethasone in reducing intimal hyperplasia in rat abdominal aortas after partial transection and primary repair.
METHODS: In this study, 20 Wistar Albino rats were randomly selected and divided into four groups to compare the effects of low- and high-dose dexamethasone on intima and media thickness compared to the control. Group A (n=5) was the control group, where only skin incision and laparotomy were performed. For Group B (n=5), a median laparotomy was performed, the abdominal aorta was partially transected, and repaired with an 8.0 prolene suture. Doses of 0.1 mg/kg and 0.2 mg/kg dexamethasone were administered in Group C (n=5) and Group D (n=5), respectively. After two weeks, all rats were euthanized, and the repaired abdominal aortas were excised and examined histopathologically. Intima and media thicknesses were measured using the 'Olympus AnalySIS 5' program (Olympus Corporation, Japan) after digital photos were taken.
RESULTS: Based on the measurements, we demonstrated that after transection and repair of the abdominal aorta, the intima/media ratio was not significantly different between the low-dose dexamethasone and non-dexamethasone groups. The intima/media ratio was significantly lower in the high-dose dexamethasone group than in the non-dexamethasone and low-dose dexamethasone groups.
CONCLUSION: After vascular interventions, dexamethasone treatment may reduce intimal hyperplasia and increase patency by providing vascular remodeling.
The control group undertook a similar RHK training regime in sequence and duration, mirroring the number of kicks performed by the experimental group, but without ER equipment. After each training session, a 5-minute rest allotted before resuming standard Taekwondo training. Post the 8-week training, both groups underwent a 2-week retention period with uniform training program.
Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
The invention discloses a manufacturing method of new lip gloss, and relates to the technical fields of beauty treatment and beauty makeup. The new lip gloss is mainly manufactured from polyvinyl alcohol and natural plant pigment, with the addition of multiple safe edible components for moistening and protecting the skin. After being applied to the lip, the lip gloss gradually air-dries in about 5 min and forms a membrane layer that can be torn down, and the color of the lip gloss is printed on the lip. During the air-drying process, the components for moistening and protecting the skin in the lip gloss play an excellent effect on skin moistening and protection. The problem that dermatitis is caused, for the lip is hurt when the lip gloss membrane formed on the lip is peeled is solved. Meanwhile, the natural plant pigment can be easily cleaned up through an oil cleansing lotion, so that the problem that allergy of the lip is caused, for the lip gloss is difficult to remove is solved.
FIELD: medicine, antituberculosis agents. SUBSTANCE: invention describes pharmaceutical composition showing antituberculosis effect that involves protionamide as an active component and special additions taken in the amount of 43.0-53.0 wt.% of active component mass and method of its preparing. Microcrystalline cellulose, potato or maize starch, hydroxypropylmethylcellulose, aerosil and magnesium or calcium stearate are used as special additions. Composition is made as tablet covered by envelope consisting of hydroxypropylmethylcellulose, Tween-80, titanium dioxide, dye orange-S. Composition can be used for treatment of patients with tuberculosis. EFFECT: stability of composition at storage, rapid release of active component in gastroenteric tract. 7 cl, 3 ex
Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 \> 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
PURPOSE:To obtain an external agent for skin, having melanogenesis suppressing action, exhibiting excellent skin beautifying effect and having high safety by using an anti-inflammatory agent and an alkoxysalicylic acid as active components. CONSTITUTION:This external agent for skin contains 0.001-5wt.% (based on the external agent) of an anti-inflammatory agent and 0.001-20-wt.% of an alkoxysalicylic acid of formula (R is an alkoxy) and/or its salt, e.g. 3- methoxysalicylic acid as active components. The skin-beautifying effect can be promoted by adding acidic mucopolysaccharides, vitamin E esters, p- oxybenzoic acid esters and alkylenediaminecarboxylic acid derivatives. The abnormal deposition of melanin pigment to the cuticle can be prevented and ameliorated by the tyrosinase activity inhibiting action of the alkoxysalicylic acids and the skin-beautifying effect is improved by the combined use of the anti-inflammatory agent. The agent can be prepared in the form of cream, milky lotion, lotion, pack, jelly, ointment, etc.
Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.
Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
The invention discloses a medicinal liquor for treating gout, which belongs to the medicine field. The medicinal liquor is used for treating gout, has better curative effect than that of the existing traditional Chinese medicines and overcomes the defects that western medicines used for treating gout have a plurality of side effects and great difficulties for radical cure. The medicinal liquor consists of traditional Chinese medicinal materials according to the following parts by weight (pbw): 40pbw to 80pbw of pilos antler, 50pbw to 80pbw of radix aconiti, 50pbw to 80pbw of radix aconiti agrestis, 80pbw to 120pbw of radices puerarire, 80pbw to 120pbw of rhizoma cibotii, 80pbw to 120pbw of achyranthes, 80pbw to 120pbw of wolfberry fruits, 80pbw to 120pbw of prepared rehmannia root, 60pbw to 100pbw of pine nodular branch, 60pbw to 100pbw of Wooly datchmanspipe herb, 80pbw to 120pbw of radix notoginseng, 50pbw to 80pbw of cassia twig, 80pbw to 120pbw of honeysuckle, 750pbw to 1250pbw ofbrown sugar and 12500pbw to 17500pbw of white spirit. The preparation method comprises the steps: solid components are put into a container, added with a proper amount of white liquor and soaked for 30 days, and then the liquor is separated to obtain the medicinal liquor. The medicinal liquor is a traditional Chinese medicine for treating gout which has the advantages of determined and obvious curative effect, high cure rate, convenient taking, easy preparation and available raw materials. The medicinal liquor overcomes the defects that western medicines used for treating gout have a plurality of side effects and great difficulties for radical cure.
The invention belongs to the field of pharmaceutical chemistry, and discloses an application of an aminodithioformate derivative in the antibacterial field. The compound can restore the sensitivity of enterobacteriaceae containing metallo-beta-lactamase to carbapenem antibiotics. In-vitro antibacterial experiment results prove that the compound can improve the drug sensitivity of MEM when being used with meropenem. Aiming at carbapenem drug-resistant NDM-1 enzyme-producing Escherichia coli, the compound can reduce the MIC value of carbapenem meropenem by about 40960 times optimally. Zinc ion sensitivity experiments preliminarily prove that zinc ions have interference on the recovery of MEM drug effect of the compound. The dynamic sterilization effect proves that the sterilization effect of the compound on the MEM is also improved well under the combination. In vitro erythrocyte toxicity experiments and cytotoxicity experiments prove that the compound has small physical toxicity and is relatively safe. The compounds can be used as candidate drugs of novel metallo-beta-lactamase inhibitors.
OXAYDO (oxycodone HCl) 5 mg and 7.5 mg tablets are an immediate-release opioid agonist intended for oral administration only.

Chemically, oxycodone HCl is 4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one HCl, a white, odorless crystalline powder. Oxycodone HCl is soluble in water (1 g in 6 to 7 mL). The molecular weight of oxycodone HCl is 351.82. The molecular formula for oxycodone HCl is C18H21NO4•HCl, and the structure is:

The inactive ingredients in OXAYDO include: colloidal silicon dioxide NF; crospovidone NF; magnesium stearate NF; microcrystalline cellulose NF; polyethylene oxide NF; and sodium lauryl sulfate NF.

The tablets are round, convex, white and debossed with the strength (5 or 7.5) on one side and the letter “O” on the other side.
Neuroinflammation is an innate and adaptive immune response initiated by the release of inflammatory mediators from various immune cells in response to harmful stimuli. While initially beneficial and protective, prolonged or excessive neuroinflammation has been identified in clinical and experimental studies as a key pathological driver of numerous neurological diseases and an accelerant of the aging process. Glycolysis, the metabolic process that converts glucose to pyruvate or lactate to produce adenosine 5'-triphosphate (ATP), is often dysregulated in many neuroinflammatory disorders and in the affected nerve cells. Enhancing glucose availability and uptake, as well as increasing glycolytic flux through pharmacological or genetic manipulation of glycolytic enzymes, has shown potential protective effects in several animal models of neuroinflammatory diseases. Modulating the glycolytic pathway to improve glucose metabolism and ATP production may help alleviate energy deficiencies associated with these conditions. In this review, we examine six neuroinflammatory diseases-stroke, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and depression-and provide evidence supporting the role of glycolysis in their treatment. We also explore the potential link between inflammation-induced aging and glycolysis. Additionally, we briefly discuss the critical role of glycolysis in three types of neuronal cells-neurons, microglia, and astrocytes-within physiological processes. This review highlights the significance of glycolysis in the pathology of neuroinflammatory diseases and its relevance to the aging process.